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DOI 10.1016/j.ccr.2010.12.022SUMMARYDespite evidence supporting an oncogenic role in breast cancer, the Notch pathway’s contribution to metas-
tasis remains unknown. Here, we report that the Notch ligand Jagged1 is a clinically and functionally impor-
tant mediator of bone metastasis by activating the Notch pathway in bone cells. Jagged1 promotes tumor
growth by stimulating IL-6 release from osteoblasts and directly activates osteoclast differentiation. Further-
more, Jagged1 is a potent downstream mediator of the bone metastasis cytokine TGFb that is released
during bone destruction. Importantly, g-secretase inhibitor treatment reduces Jagged1-mediated bone
metastasis by disrupting the Notch pathway in stromal bone cells. These findings elucidate a stroma-depen-
dent mechanism for Notch signaling in breast cancer and provide rationale for using g-secretase inhibitors
for the treatment of bone metastasis.INTRODUCTION
The Notch-signaling pathway regulates a broad spectrum of cell-
fate decisions during development and postnatal life (Artavanis-
Tsakonas et al., 1999). The pathway is activated when a signal-
sending cell expressing a Notch ligand physically interacts with
a signal-receiving cell expressing a Notch receptor. Upon ligand
binding, the transmembrane Notch receptor is cleaved sequen-
tially, first by an extracellular matrix metalloprotease and then by
the protease complex g-secretase, releasing the Notch intracel-
lular domain (NICD). After being liberated, NICD translocates to the
nucleus where it interacts with the DNA-binding protein CSL
(Rbp-Jk in mice; CBF1 in humans), converting it from a transcrip-
tional repressor to activator by recruiting cofactors such as
Mastermind-like proteins. The most prominent targets of the
Notch pathway include a set of basic-helix-loop-helix factors of
the Hes and Hey families (Kopan and Ilagan, 2009).Significance
Although Notch pathway activation leads to tumorigenesis, lit
Here, we report that elevated expression of the Notch ligand
Functional studies revealed that tumor-derived Jagged1 prom
vating the Notch pathway in the bone microenvironment. Thes
in breast cancer, as we define a requirement for the pathway in
than the tumor cells. Importantly, pharmacological inhibition o
mediated bone metastasis and provided preclinical evidence fo
bone metastasis.
192 Cancer Cell 19, 192–205, February 15, 2011 ª2011 Elsevier Inc.Although classically known for its role in embryonic develop-
ment, the Notch pathway is now being recognized for its aber-
rant activation in cancer. An oncogenic role for Notch was first
discovered in T cell acute lymphoblastic leukemia (T-ALL), and
then extended to other malignancies including lung, ovary,
breast, and skin cancers (reviewed by Rizzo et al., 2008). Only
recently has Notch signaling been associated with cancer
progression; it was shown to regulate mediators of invasion in
pancreatic cancer (Wang et al., 2006) and promote epithelial-
mesenchymal transition (Leong et al., 2007). Interestingly, the
Notch ligand Jagged1 is also associated with cancer progres-
sion because it is overexpressed in patients with poor prognosis
prostate and breast cancer (Reedijk et al., 2005; Santagata et al.,
2004). Despite these advances, the functional mechanism of the
Notch pathway in breast cancer metastasis is poorly defined.
Bonemetastasis affects over 70%ofmetastatic breast cancer
with debilitating bone fractures, severe pain, nerve compression,tle is known about the role of Notch signaling in metastasis.
Jagged1 is associated with breast cancer bone metastasis.
otes osteolytic bone metastasis of breast cancer by acti-
e findings establish a distinct paradigm for Notch signaling
the supporting microenvironment of bonemetastases rather
f the Notch pathway in stromal bone cells reduced Jagged1-
r using g-secretase inhibitors as therapeutic agents against
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Jagged1 Promotes Breast Cancer Bone Metastasisand hypercalcemia (Mundy, 2002). The development and
outgrowth of these secondary lesions depend on the intricate
cellular and molecular interactions between breast tumor cells
and stromal cells of the bone microenvironment. In particular,
the ability of tumor cells to disrupt the bone homeostatic balance
maintained by two resident bone cell types, osteoclasts and
osteoblasts, has been shown to drive bone destruction and
metastatic tumor growth (Mundy, 2002). Tumor cells secrete
signaling proteins, such as parathyroid hormone-related peptide
(PTHrP) (Guise et al., 1996), to promote osteoclast differentiation
and activity, either directly or indirectly by altering osteoblast
production of receptor activator of nuclear factor-kB ligand
(RANKL), an essential osteoclast differentiation cytokine, and
its antagonist osteoprotegerin (OPG). The resultant bone
destruction releases a number of growth factors stored in the
bone matrix, such as transforming growth factor-b (TGFb), to
further stimulate the malignancy of tumor cells, completing the
so-called ‘‘vicious cycle’’ in bone metastasis. Although several
molecular contributors of bone metastasis have been identified,
effective therapies still await a more comprehensive under-
standing of the complex molecular and cellular network of
tumor-stromal interactions in bone metastasis. In this study we
investigated the role of Notch signaling in the development of os-
teolytic bone metastasis of breast cancer.
RESULTS
The Notch Ligand Jagged1 Is Associated with Breast
Cancer Bone Metastasis
To investigate the potential role of Notch signaling in breast
cancer metastasis, we evaluated the endogenous expression
of pathway ligands, receptors, and downstream targets in the
4T1 series of mouse mammary tumor cell lines with increasing
metastatic abilities (Aslakson and Miller, 1992). Although all of
the cell lines in this series form primary tumors with similar
growth kinetics, only 4T1 is capable of developing bone metas-
tasis spontaneously (Lelekakis et al., 1999). Gene expression
analysis of the Notch pathway receptors and prominent down-
stream targets revealed no association with metastatic ability
(see Figures S1A and S1B available online). In contrast, Notch
ligand levels were markedly elevated in the 4T1 cell line
(Figure 1A; Figure S1C). Moreover, expression profiling of human
MDA-MB-231 (MDA231) breast cancer sublines with distinct
bone metastatic abilities (Kang et al., 2003) revealed that
JAGGED1 (JAG1) levels were significantly elevated in aggressive
bone-tropic sublines compared to the weakly metastatic ones
(Figure 1B; Figure S1D) (p < 0.01). These findings suggested
a possible link between tumor expression of Notch ligands and
breast cancer bone metastasis.
To determine the clinical significance of Jagged1 in breast
cancer metastasis, we examined its expression pattern in tumor
samples from patients in two previously reported data sets. The
Wang data set (Wang et al., 2005) revealed that JAG1 expression
was significantly higher in patients with relapse (p = 0.0045,
Student’s t test). Moreover, incidence of relapse was signifi-
cantly greater in patients with high JAG1 expression compared
to those with low expression (Figure 1C). In contrast the
incidence of relapse was not significantly different in patients
with low or high expression of NOTCH1 or HES1 (Figures S1E–CS1G). Distinct from the Wang data set, the Minn data set
(Minn et al., 2005) includes more diverse clinical criteria such
as organ-specific metastasis. The incidence of bone metastasis
was significantly greater in patients with high JAG1 expression
compared to those with low expression (Figure 1D). In contrast,
the incidence of bone metastasis was not significantly different
between patients with differential expression of NOTCH2,
NOTCH3, and NOTCH4 (Figures S1H–S1J) (NOTCH1 expres-
sion is too low for analysis). These findings further implicate
Jagged1, in contrast to the Notch receptors or other pathway
components, as a clinically significant player in breast cancer
metastasis to the bone.
Jagged1 Mediates Breast Cancer Bone Metastasis
To directly test whether Jagged1 is functionally important for
breast cancer bone metastasis, we used a short-hairpin RNA
(shRNA) to stably silence its expression in SCP2 and 1833 (Fig-
ure 1E), two highly bone metastatic MDA231 sublines with high
expression of JAG1 (Figure 1B). The progression of bone metas-
tasis after intracardiac injection of tumor cells was monitored by
weekly bioluminescence imaging (BLI) using a stably expressed
firefly luciferase reporter. JAG1 knockdown (KD) significantly
extended survival (Figure 1F) and delayed the onset of bone
metastasis in mice (Figures S1K and S1L). Despite no difference
at early time points, BLI analysis showed that JAG1 KD reduced
the bone tumor burden by 6- to 10-fold 3 weeks after injection
(Figure 1G; Figures S1M and S1N), suggesting that tumor-
derived Jagged1 is necessary for efficient outgrowth of bone
lesions. We confirmed that the differences in BLI measurement
of bone tumor burden corresponded to those achieved by histo-
morphometric and X-ray analyses (Figures 1H–1J; Figure S1M–
S1O). Consistent with these results, histological analysis demon-
strated a 2-fold decrease in the number of tartrate-resistant acid
phosphatase-positive (TRAP+) osteoclasts along thebone-tumor
interface of bone lesions generated by JAG1KD cells (Figures 1K
and 1L). Importantly, JAG1 KD did not alter the ability of tumor
cells to proliferate in culture or as mammary tumors in mice
(Figures S1P–S1R). These results support a functional role for
tumor-derived Jagged1 in bone metastasis, in part by its ability
to support efficient tumor outgrowth and induce osteolysis.
To determine whether enforced expression of Jagged1 is
sufficient to promote bone metastasis, we overexpressed it in
the mildly metastatic MDA231 subline SCP28 (Figures S2A and
S2B). Mice injected with JAG1 overexpressing (OE) tumor cells
had an earlier onset of bone metastasis (Figure 2A), demon-
strated a significant increase in bone metastasis burden by BLI
(Figure 2B), and developed severe osteolytic bone lesions as
determined by X-ray and histological analysis (Figures 2C–2E).
Ki67 staining of bone metastases revealed a greater number of
proliferating cancer cells in the JAG1 OE group (Figure 2F).
In contrast, JAG1 OE did not increase the proliferation of tumor
cells in culture or as primary mammary tumors, and did not affect
their invasive ability in vitro (Figures S2C–S2E). Importantly, we
found that Notch pathway target genes were elevated in the
tumor-associated stroma of JAG1 OE bone metastases (Fig-
ure S2F) using mouse-specific RT-PCR analysis. These findings
indicate that enforced expression of Jagged1 is sufficient to
promote osteolytic bone metastasis, potentially by activating
the Notch pathway in the supporting bone microenvironment.ancer Cell 19, 192–205, February 15, 2011 ª2011 Elsevier Inc. 193
Figure 1. Tumor-Derived Jagged1 Is Associated with High Risk for Bone Metastasis and Functionally Important for Osteolytic Bone
Metastasis In Vivo
(A) Heat map depicting microarray gene-expression profiling of Notch pathway ligands across the 4T1 series.
(B) mRNA expression of JAG1 in the MDA231 cell line and its derivative sublines with distinct bone metastasis properties using qRT-PCR.
(C and D) Kaplan-Meier relapse-free survival curve of patients from the Wang data set (Wang et al., 2005) (C) and bone metastasis-free survival curve of the Minn
data set (Minn et al., 2005) (D) with either low or high expression of JAG1.
(E) Western blot analysis showing JAGGED1 protein levels in the control and JAG1 KD SCP2 and 1833 sublines.
(F) Kaplan-Meier survival curve of mice (n = 10) inoculated with control or JAG1 KD SCP2 cells.
(G) Normalized BLI signals of bone metastases of mice (n = 10) from each experimental group. *p < 0.05 by Mann-Whitney test.
(H) Histomorphometric quantification of tumor area of bone lesions from each experimental group.
(I) BLI, X-ray, and histological images of bone lesions from representative mice in each experimental group. Red arrows indicate osteolytic bone lesions. Scale
bar, 6 mm.
(J) Quantification of hindlimb osteolysis from mice in each experimental group using X-ray analysis.
(K) Quantification of TRAP+ osteoclasts along the bone-tumor interface of metastases of mice from each experimental group.
(L) H&E and TRAP staining of bone metastasis from each experimental group. Arrows indicate TRAP+ osteoclasts. Arrowheads indicate areas of overt bone
destruction. Scale bar, 200 mM.
Data in the figure represent average ± SEM; p values were based on Student’s t test unless otherwise indicated. See also Figure S1.
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Jagged1 Promotes Breast Cancer Bone MetastasisConsidering the importance of the immune system in bone
homeostasis (Pacifici, 2010) and the pathogenesis of bone
metastasis (Xu et al., 2009), we extended our analysis to an
immunocompetent mouse model for bone metastasis. Using
the BALB/c-derived TM40D-MB murine breast cancer cell
line (Li et al., 2008), we overexpressed mouse Jagged1 and
tested its ability to promote metastasis in vivo. The results
showed a significant increase in bone metastasis ability for
the Jag1 OE group in both immunocompetent BALB/c and
athymic nude mice (Figures S2G–S2K). These findings suggest
that immune cells are unlikely to play a critical role in mediating
the bone metastasis-promoting function of tumor-derived
Jagged1.194 Cancer Cell 19, 192–205, February 15, 2011 ª2011 Elsevier Inc.Jagged1 Is Regulated by the TGFb-SMAD Signaling Axis
in Bone Metastasis
Expression of prometastatic genes is often influenced by
signaling molecules present in the pathological milieu of the
tumor microenvironment. To identify potential regulators of
Jagged1 in the bone microenvironment, we examined the
enrichment of various signaling pathway target gene sets in the
transcriptome of bone metastatic tumor cells. Gene-set enrich-
ment analysis demonstrated that TGFb-responsive genes are
significantly overrepresented among upregulated genes in
bone metastatic MDA231 sublines (Figure 3A, p = 0.0212).
Notably, JAG1 was revealed among the 10-gene enrichment
core of TGFb responsive genes (Figure 3A), suggesting that it
Figure 2. Enforced Expression of Jagged1 in Breast Cancer Promotes Osteolytic Bone Metastasis
(A) Kaplan-Meier bone metastasis-free survival curve of mice inoculated with control or JAG1 OE SCP28 cells (n = 10).
(B) Normalized BLI signals of bone metastases of mice from each experimental group. **p < 0.01, *p < 0.05.
(C) Quantification of X-ray osteolytic lesion area of hindlimbs from each experimental group.
(D) Quantification of TRAP+ osteoclasts along the bone-tumor interface of metastases from each experimental group.
(E) BLI, X-ray, and histological (H&E and TRAP) images of bone lesions from two representative mice in each experimental group on day 42. Red arrows indicate
osteolytic bone lesions in the X-ray images and tumor burden in the histological images. JAG1 images have been stained using IHC against JAGGED1. Scale bar,
200 mM.
(F) The top panel shows Ki67 immunohistochemical images of bone metastases from each experimental group. Scale bar, 200 mM. The bottom panel illustrates
quantification of percent Ki67+ tumor cells along bone-tumor interface of five distinct 203 images from each group (n = 3).
Data in the figure represent average ± SEM; p values were based on Student’s t test unless otherwise indicated. See also Figure S2.
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Jagged1 Promotes Breast Cancer Bone Metastasisis a potential target of TGFb in breast cancer cells during
osteolytic bone metastasis. Indeed, Jagged1 is potently upregu-
lated in several breast cancer cell lines upon TGFb stimulation
(Figure 3B; Figures S3A and S3B). TGFbReceptor 1 kinase inhib-
itor treatment abolished this induction in breast cancer cells
in vitro (Figures S3C and S3D) and in bone metastases in vivo
(Figure S3E). Furthermore, using our previously reported
SCP28 subline with conditional expression of SMAD4 (Korpal
et al., 2009), we demonstrated a SMAD-dependent transcrip-
tional regulation of JAG1 by TGFb signaling (Figure 3C;
Figure S3F).
We next investigated whether Jagged1 is an important down-
stream effector of the prometastatic TGFb-SMAD signaling
pathway during bone metastasis in vivo. As previously reported,
SMAD4 KD significantly inhibits the development of osteolytic
bone metastasis (Kang et al., 2005) (Figures 3D–3F). We
reasoned that if Jagged1 is an important TGFb target during
bone metastasis, overexpressing it in SMAD4 KD cells mayCpartially restore their aggressive bone metastatic ability. Indeed,
JAG1OE strongly rescued the ability of SMAD4KD tumor cells to
generate osteolytic bone metastases (Figures 3D–3H). Further-
more, the reduced bone metastasis burden observed in the
JAG1 KD experiments could also be explained in part by the
inability of the JAG1 KD tumor cells to induce JAGGED1 expres-
sion in response to bone-derived TGFb (Figure S3G). Taken
together, these findings demonstrate that TGFb, a well-known
prometastatic cytokine, stimulates Jagged1 expression in
cancer cells to promote osteolytic bone metastasis.
Jagged1 Confers a Growth Advantage by Activating
Notch Signaling in Osteoblasts
Because manipulating Jagged1 expression influenced the
development of bonemetastasis without affecting primary tumor
functions (Figures S1 and S2), it is likely that Jagged1-Notch
signaling facilitates communication between tumor cells and
the bone microenvironment to promote metastasis. Therefore,ancer Cell 19, 192–205, February 15, 2011 ª2011 Elsevier Inc. 195
Figure 3. Jagged1 Is a Functional Target of the TGFb-SMAD Signaling Pathway in Breast Cancer Bone Metastasis
(A) Gene-set enrichment analysis of the TGFb-response gene set in a ranked list of differentially expressed genes in strongly versus weakly bone-metastatic
MDA231 sublines (p = 0.0212). The right panel shows corresponding heat map of core TGFb gene set with elevated expression in strongly (red) versus weakly
(green) bone-metastatic MDA231 sublines.
(B) mRNA expression of JAG1 in response to TGFb treatment in theweakly (green) and strongly (red) bone-metastaticMDA231 sublines using previously reported
microarray expression profiling data (Kang et al., 2003).
(C) qRT-PCRmRNA expression levels of JAG1 in the SCP28 cell line with inducible (Tet-off) SMAD4 expression (Korpal et al., 2009) under the indicated TGFb and
doxycycline treatment conditions. Data represent average ± SD.
(D) Western blot analysis showing JAGGED1 and SMAD4 protein levels in the indicated cell lines with altered expression of JAGGED1 and SMAD4.
(E) BLI and X-ray images of bone lesions of three representative mice from each experimental group on day 42. White arrows indicate osteolytic lesions in the
X-ray images.
(F) Normalized BLI signals of bone metastases in the hindlimbs of mice (n = 10) from each experimental group. **p < 0.01, *p < 0.05 by Student’s t test.
(G) Kaplan-Meier bone metastasis-free survival curve of mice (n = 10) from each experimental group.
(H) Quantification of radiographic osteolytic lesion area of hindlimbs from each experimental group.
Student’s t test p < 0.001. Data in the figure represent average ± SEM unless otherwise indicated. See also Figure S3.
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Jagged1 Promotes Breast Cancer Bone Metastasiswe investigated the involvement of supporting bone cells, partic-
ularly osteoblasts and osteoclasts, in Jagged1-mediated bone
metastasis by employing an in vitro coculture system.
We first tested the ability of tumor-derived Jagged1 to activate
the Notch pathway in associated osteoblasts. When MC3T3-E1
osteoblasts expressing a Notch reporter (Zeng et al., 2005) were
cocultured with JAG1 OE tumor cells, we observed a 6-fold
increase in Notch activity that was abolished by the g-secretase
inhibitor (GSI) MRK-003 (Figure 4A). Moreover, osteoblasts
separated by FACS from cocultured JAG1 OE GFP+ tumor cells
(Figures S4A and S4B) demonstrated activation of several Notch
target genes that were downregulated by MRK-003 treatment
(Figure 4B).196 Cancer Cell 19, 192–205, February 15, 2011 ª2011 Elsevier Inc.Considering the elevated proliferative index (Ki67+) of JAG1
OE bone metastases (Figure 2F), we investigated whether the
growth advantage was acquired via interactions with
osteoblasts. We tested this by culturing GFP+-luciferase labeled
tumor cells over a monolayer of MC3T3-E1 osteoblasts and
subsequently quantifying tumor proliferation via luciferase
assay. The results showed a 2-fold increase in the number of
JAG1 OE tumor cells compared to vector controls when normal-
ized to the counts of either population cultured without osteo-
blasts (no coculture) (Figures 4C and 4D). Moreover, JAG1 OE
tumor cells formed GFP+ colonies that were 2.5-fold larger in
diameter (Figure 4E). MRK-003 treatment abolished the growth
advantage of JAG1 OE tumor cells in the osteoblast coculture
Figure 4. Jagged1-Expressing Tumor Cells Have a Growth Advantage in the Bone Microenvironment via Notch-Dependent Crosstalk with
Osteoblasts
(A) Coculture between control or JAG1 OE SCP28 tumor cells andMC3T3-E1 osteoblasts transfected with a Notch reporter and treated with DMSO or MRK-003.
(B) qRT-PCR mRNA expression levels of indicated Notch target genes and TGFb1 in MC3T3-E1 osteoblasts that were FACS-separated from cocultures in each
experimental group. *p < 0.05, **p < 0.01, ***p < 0.001.
(C) Representative images of cocultures from each experimental group. White boxes indicate areas shown at higher magnification in the middle row. Tumor cells
cultured alone are shown in the bottom row. Scale bar, 200 mM.
(D) Quantification of tumor cells from cocultures with MC3T3-E1 from each experimental group by luciferase assay. *p = 0.01, **p = 0.007.
(E) Diameter of tumor colonies from cocultures of each experimental group. ***p < 107.
(F) Quantification of tumor cells cultured alone from each experimental group.
Data in the figure represent average ± SD; p values were based on Student’s t test. See also Figure S4 and Table S1.
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Jagged1 Promotes Breast Cancer Bone Metastasis(Figures 4C–4E and 5A) but did not affect their proliferative ability
when cultured alone (Figure 4F; Table S1). These results were
also confirmed in primary bone marrow osteoblast cocultures
(Figures S4C and S4D). Furthermore, genetic inhibition of Notch
signaling in MC3T3-E1 via siRNA-mediated silencing of Rbpj, an
indispensable cofactor of the Notch pathway, diminished the
ability of JAG1 to stimulate tumor cell proliferation in cocultures
(Figure 5B). Collectively, these findings revealed that activation
of the Notch pathway in osteoblasts confers a proliferative
advantage to JAG1 OE tumor cells.
To identify Jagged1-regulated genes in osteoblasts that are
potentially required for the enhanced tumor growth properties,
we performed microarray profiling of the MC3T3-E1 cells that
were FACS-separated from tumor cell cocultures (Figure S4B).
Transcriptomicprofilinguncovered123genes thatwere activated
by at least 3-fold in MC3T3-E1 cells cocultured with JAG1 OE
tumor cells relative to controls. These genes were concomitantly
downregulated in the MRK-003-treated groups (Figure 5C).CAs expected, many well-characterized Notch targets were found
among these candidate genes. We proceeded to investigate the
necessity of Hey1, the most upregulated downstream mediator
of the Notch pathway, by silencing its expression in MC3T3-E1
(Figure S4E). Hey1 KD in MC3T3-E1 significantly diminished the
coculture growth of JAG1 OE tumor cells (Figure 5E), suggesting
that Hey1 is a required downstream mediator of Notch signaling
in osteoblasts for promoting tumor growth.
Next, we sought to identify Notch-dependent signaling
proteins secreted by osteoblasts that may potentially stimulate
tumor growth. The most promising candidate from the ranked
gene list was interleukin-6 (IL-6) (Figure 5D) because it is impli-
cated in the development of bone metastasis (Ara et al., 2009;
de la Mata et al., 1995) and associated with poor clinical
outcome in patients with breast cancer (Salgado et al., 2003).
JAG1 OE cocultures demonstrated a 7-fold increase in IL-6
levels by ELISA (Figures 5F–5H). Importantly, IL-6 was selec-
tively secreted by osteoblasts since conditioned media fromancer Cell 19, 192–205, February 15, 2011 ª2011 Elsevier Inc. 197
Figure 5. IL-6 Is Secreted by Osteoblasts in a Notch- and Hey1-Dependent Fashion and Stimulates the Growth of Jagged1-Expressing
Tumor Cells
(A) Quantification of control or JAG1 OE tumor cells cocultured with MC3T3-E1 cells and treated with DMSO, 1 mM, or 5 mM MRK-003 by luciferase assay.
*p < 0.05.
(B) Quantification of indicated tumor cells cocultured with MC3T3-E1 cells that were treated with Rbpj siRNAs by luciferase assay. *p < 0.05.
(C) Heat map depicting microarray gene expression profiling of MC3T3-E1 osteoblasts that were FACS-separated from cocultures of each experimental group.
(D) A list of genes with expression levels greater than 3-fold in osteoblasts cocultured with JAG1 OE tumor cells relative to controls.
(E) Quantification of indicated tumor cells cocultured with MC3T3-E1 cells that were treated with Hey1 siRNAs by luciferase assay. **p < 0.005.
(F) Quantification of IL-6 levels in conditionedmedia of control or JAG1OE tumor cells cultured alone or coculturedwithMC3T3-E1 cells in the presence of DMSO,
1 mM, or 5 mM MRK-003 using ELISA. ***p < 1 3 105.
(G) ELISA quantification of IL-6 levels in conditioned media of indicated tumor cells cocultured with MC3T3-E1 cells treated with Rbpj siRNAs. **p < 0.0005,
***p < 1 3 104.
(H) Quantification of IL-6 levels in conditioned media of indicated tumor cells cocultured with MC3T3-E1 cells treated with Hey1 siRNAs using ELISA.
***p < 0.0005.
(I) Quantification of indicated tumor cells cocultured with MC3T3-E1 cells and treated with IgG, 0.5 mg/ml, or 1.0 mg/ml anti-mouse IL-6 by luciferase assay.
*p < 0.05, **p = 0.007.
(J) Quantification of indicated tumor cells cocultured with MC3T3-E1 cells and treated with PBS, 10 ng/ml, or 100 ng/ml hIL-6 by luciferase assay. *p < 0.05,
***p < 1 3 105.
Data in the figure represent average ± SD; p values were based on Student’s t test.
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(Figure 5F); this is consistent with the observation that JAG1
OE promotes tumor cell growth only in the presence of
MC3T3-E1 cells. IL-6 transcription and secretion from osteo-
blasts were dependent on the Notch pathway, as shown by
MRK-003 and Rbpj siRNA treatments (Figures 5F and 5G; Fig-
ure S4F). Furthermore, we validated that Hey1 regulates both
mRNA and protein levels of IL-6 (Figure 5H; Figure S4G). Based
on these results, we proceeded to test whether Notch-stimu-198 Cancer Cell 19, 192–205, February 15, 2011 ª2011 Elsevier Inc.lated IL-6 secretion from osteoblasts was required for the
enhanced tumor proliferation. Inhibition of osteoblast-derived
IL-6 by a neutralizing antibody diminished the growth advantage
of JAG1 OE tumor cells (Figure 5I). Conversely, stimulation of
control tumor cells by rIL-6 significantly enhanced their prolifer-
ative ability (Figure 5J). These findings outline a positive feed-
back signaling axis by which Jagged1-Notch signaling stimu-
lates the release of IL-6 from osteoblasts to promote tumor
proliferation.
Figure 6. Jagged1-Expressing Tumor Cells Stimulate Osteoclastogenesis and Osteolytic Bone Lesions via Notch-Dependent Signaling
(A) TRAP staining of cocultures of control or JAG1 OE tumor cells with pre-osteoclast Raw 264.7 cells treated with DMSO or 1 mM MRK-003 immediately after
seeding in the displayed 12-well plate (Early).
(B) TRAP staining of similar experiment as (A) except DMSO or 1 mM MRK-003 treatment was initiated 2 days after seeding (Late).
(C) qRT-PCR mRNA expression levels of mouse Apc5 (encoding mouse TRAP) from the experimental groups described in (A) and (B). **p = 0.001, ***p < 104,
#p > 0.4.
(D) Quantification of TRAP+ osteoclasts from experiment (A). **p < 1 3 104.
(E) Diameter of TRAP+ osteoclasts from experiment (A). ***p < 1 3 107.
(F) Quantification of TRAP+ osteoclasts with the indicated number of nuclei from experiment (A). Number of osteoclasts quantified per group is 86.
(G) Representative images of TRAP+ osteoclasts from experiment (A). Scale bar, 400 mM.
(H) Heat map depicting qRT-PCRmRNA expression levels of osteoclast differentiation markers in Raw 264.7 cells that have been cocultured under the indicated
conditions using mouse-specific primers.
Data in the figure represent average ± SD; p values were based Student’s t test. See also Figure S5.
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Differentiation
The severe osteolytic phenotype observed in Jagged1-mediated
bone metastases could be explained by two possible mecha-
nisms. JAGGED1-expressing tumor cells may indirectly impact
osteoclast activity by altering the expression of osteoblast-
derived Rankl and Opg. Alternatively, JAG1 OE tumor cells
may directly interact with pre-osteoclasts to stimulate their
maturation. The first possibility was ruled out by the observation
that there was no difference in mRNA and protein levels of Rankl
and Opg in MC3T3-E1-tumor cell cocultures from each experi-
mental condition (Figures S5A–S5E). Moreover, the conditioned
media from these cocultures did not impact osteoclast proper-
ties (data not shown). Therefore, we proceeded to test the
second possibility by directly coculturing tumor cells with
pre-osteoclast Raw 264.7 cells. Strikingly, JAG1 OE coculturesCshowed a 15-fold increase in TRAP+ osteoclasts relative to
controls, whereas MRK-003 treatment essentially abolished
this phenotype (Figures 6A and 6D). These findings were
confirmed in primary osteoclast cocultures (Figures S5F–S5I)
and by using recombinant JAGGED1 protein (rJAG1) alone,
a different GSI (GSI IX), and an additional murine osteoclast
precursor cell line (MOCP5) (Figures S5J–S5O). Delayed initia-
tion of MRK-003 treatment (Late) failed to fully rescue the pheno-
type, as shown by Acp5 (mouse gene encoding TRAP) mRNA
levels (Figures 6B and 6C), implying that JAGGED1 facilitates
an early stage in osteoclast maturation. Furthermore, TRAP+
osteoclasts in JAG1 OE cocultures were significantly larger
(Figures 6E and 6G) and contained more nuclei (Figure 6F),
suggesting more efficient osteoclast fusion and accelerated
differentiation. In contrast, cocultures treated with MRK-003
displayed smaller osteoclasts with fewer nuclei (Figures 6E–6G).ancer Cell 19, 192–205, February 15, 2011 ª2011 Elsevier Inc. 199
Figure 7. Disrupting the Notch Pathway with MRK-003 Reduces Osteolytic Bone Metastasis
(A) Normalized BLI signals of bonemetastasis in mice (n = 10) that have been injected with SCP2 cells and treated with vehicle or MRK-003. *p < 0.05, **p < 0.005.
(B) BLI and X-ray images of bone lesions from four representative mice in each experimental group.
(C) Kaplan-Meier bone metastasis-free survival curve of mice from each experimental group.
(D) Quantification of total and hindlimb bone lesions in vehicle or MRK003-treated mice. *p < 0.05.
(E) Quantification of radiographic osteolytic lesion area of hindlimbs of mice from each experimental group.
(F) Quantification of TRAP+ osteoclasts along the bone-tumor interface of metastases of mice from each experimental group.
(G) Histological (H&E and TRAP staining) analysis of bone metastases from each experimental group. Arrowheads indicate bone destruction in histological
sections of vehicle mice. Scale bar, 200 mM.
(H) qRT-PCR mRNA expression of Notch target genes and mouse IL-6 in the stromal compartment of bone metastasis from vehicle or MRK-003-treated mice
using mouse-specific primers. *p < 0.005, **p < 0.001.
Data in the figure represent average ± SEM; p values were based on Student’s t test unless otherwise indicated.
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levels of osteoclast differentiation markers in Raw 264.7 cells.
As anticipated, expression of several markers was elevated
in the JAG1 OE cocultures and suppressed in the MRK-
003-treated cocultures (Figure 6H). Taken together, these
results demonstrate that JAGGED1-expressing tumor cells are
capable of directly activating osteoclasts and help provide
a mechanistic explanation for the severe osteolytic phenotype
observed in mice.
Disruption of Notch Signaling in the Bone
Microenvironment Reduces Bone Metastasis
We next asked whether MRK-003 treatment can reduce bone
metastasis by targeting the supporting bone microenvironment.200 Cancer Cell 19, 192–205, February 15, 2011 ª2011 Elsevier Inc.To this end, mice were inoculated with the aggressive bone-
tropic subline SCP2, which expresses high endogenous JAG1
levels (Figure 1B), and concomitantly treated with MRK-003.
MRK-003 treatment led to a 5-fold reduction in bone metastasis
burden by BLI and an approximate 10-day delay in the onset of
bone metastasis (Figures 7A–7C). The number of bone lesions
was also reduced in the MRK-003-treated group (Figure 7D),
which was accompanied by a 2-fold reduction in X-ray lesion
area (Figures 7B and 7E) and a 3-fold decrease in the number
of TRAP+ osteoclasts (Figures 7F and 7G). In contrast the growth
rate of primary mammary tumors was not altered by MRK-003
treatment (data not shown), suggesting that direct targeting of
Notch signaling in tumor cells cannot explain the reduced tumor
burden in the bone metastasis experiments. We also confirmed
Figure 8. Disrupting the Notch Pathway with MRK-003 Reverses Jagged1-Mediated Bone Metastasis
(A) BLI, X-ray, and histological images of bone lesions from representative mice in each experimental group on day 42. Scale bar, 200 mM.
(B) The left graph shows Kaplan-Meier bone metastasis-free survival curve of mice from each experimental group over time. Log rank p = 0.032. The right graph
illustrates normalized BLI signals of bone metastasis in mice inoculated with control or JAG1 OE tumor cells and treated with vehicle or MRK-003. *p < 0.05,
**p < 0.01 based on repeated-measures ANOVA.
(C) Quantification of radiographic osteolytic lesion area of mice hindlimbs from each experimental group. *p < 0.05 by Student’s t test.
(D) Quantification of TRAP+ osteoclasts along the bone-tumor interface of metastases from each experimental group. **p < 0.005, ***p < 1 3 104 by Student’s
t test.
(E) Schematic depicting tumor-stroma interactions of JAGGED1-expressing tumor cells with the bone microenvironment. See text for details.
Data in the figure represent average ± SEM.
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compartment of bone metastases since expression levels of
several Notch target genes, as well as IL-6, were significantly
reduced in the stromal compartment of MRK-003-treated bone
metastases, as measured by species-specific qRT-PCR
(Figure 7H).
We further tested whether MRK-003 treatment could reverse
the severe bone metastasis phenotype induced by JAG1 OE.
The significant increase in bone metastasis observed in the
JAG1 OE group was reduced by more than 6-fold when the
mice were treated with MRK-003, decreasing the tumor signal
to levels found in the control group (Figures 8A–8C). Mirroring
these changes in bone tumor dynamics, osteolysis was also
reduced in MRK-003-treated mice (Figures 8B–8D). Overall,
these preclinical studies confirm that the severe osteolytic
bone metastasis phenotype mediated by Jagged1-expressing
breast cancer is dependent on stromal Notch activation and is,
therefore, susceptible to pharmacological inhibition of the Notch
pathway in the bone microenvironment.CDISCUSSION
In this study we show that elevated expression of Jagged1 in
breast cancer cells promotes bone metastasis by activating
the Notch pathway in supporting bone cells (Figure 8E). Jagged1
is overexpressed in bone metastatic tumor cells and is further
activated by the bone-derived cytokine TGFb during osteolytic
bone metastasis. Jagged1-expressing tumor cells acquire
a growth advantage in the bonemicroenvironment by stimulating
the release of IL-6 from osteoblasts and exacerbate osteolytic
lesions by directly activating osteoclast maturation. Importantly,
GSI treatment reversed these prometastatic functions of
Jagged1 by disrupting the Notch pathway in associated bone
cells. Our findings support a distinct paradigm for the involve-
ment of Notch signaling in the progression of breast cancer.
Notch Activation in Tumor versus Stroma
The majority of studies that implicate Notch signaling in breast
cancer progression investigate its activation in tumor cells. Theancer Cell 19, 192–205, February 15, 2011 ª2011 Elsevier Inc. 201
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frommouse mammary tumor virus studies in which tumor devel-
opment frequently resulted from the expression of a truncated,
constitutively active form of the Notch receptor (Jhappan et al.,
1992). However, it is important to note that mutations that lead
to truncated forms of the Notch receptors are rare in human solid
tumor malignancies. Our investigation demonstrated that the
Notch pathway receptors and select downstream targets are
not associated with breast cancer progression. In contrast, we
revealed that elevated expression of Notch pathway ligands is
associated with metastatic ability of breast cancer cells and,
furthermore, showed that high expression of JAG1 in particular
correlates with breast cancer bone metastasis in patient
samples. Many independent studies have also supported an
association between Notch pathway ligands and human cancer
progression (Dickson et al., 2007; Santagata et al., 2004). More-
over, gene expression analysis of 58 human breast cancer
metastasis samples revealed JAG1 as one of 17 cytokine/ligand
genes overexpressed in bone metastasis compared to liver,
brain, and lungmetastasis, implicating a potential organ-specific
role for tumor-derived Jagged1 in metastatic colonization of the
bone (Zhang et al., 2009). Despite the existence of these correl-
ative relationships, little progress has been previously made
regarding the precise mechanism underlying the involvement
of Notch pathway ligands in breast cancer metastasis.
Notch Signaling in the Tumor-Associated Stroma
There is emerging evidence that activation of developmental
signaling pathways in the tumor-associated stroma facilitates
cancer progression (Sethi and Kang, 2011). A recent study
revealed that aberrant activation of the sonic hedgehog (SHH)
signaling pathway in the tumor-associated stromal microenvi-
ronment supported primary tumor growth in xenografts (Yauch
et al., 2008). Our study shows that tumor-derived Jagged1 can
facilitate outgrowth of bone metastases by activating the Notch
signaling pathway in two major residential cell types specific to
the bone microenvironment. Importantly, bone-specific cells
can also express Jagged1 (Weber and Calvi, 2010; Weber
et al., 2006) and regulate hematopoietic stem cell niches via
Notch signaling (Calvi et al., 2003). Therefore, it is conceivable
that tumor-derived Jagged1 may be capable of stimulating the
expansion of hematopoietic niches, which may potentially
support the colonization of tumor cells in the bone microenviron-
ment. Such a scenario warrants further investigation, as we do
not evaluate the involvement of other stromal cells, including
endothelial cells and hematopoietic stem cells, in Jagged1-
mediated bone metastasis.
Activation of the Notch pathway in murine stromal cells has
been reported to promote osteoblast differentiation (Nobta
et al., 2005; Tezuka et al., 2002). Conversely, loss- and gain-
of-function experiments in mice demonstrated that Notch
signaling directly inhibits osteoblast differentiation (Engin et al.,
2008; Hilton et al., 2008). These studies suggest a context-
dependent role of Notch signaling in osteoblast function (Zanotti
and Canalis, 2010). Some of our gene expression analysis
(Runx2 andOsx) pointed to a very modest increase of osteoblast
differentiation in JAG1 OE cancer cell cocultures (Figure S4C).
However, unlike the strong impact of Jagged1 on osteoclast
maturation, it was unclear whether the modest differentiation202 Cancer Cell 19, 192–205, February 15, 2011 ª2011 Elsevier Inc.of osteoblasts directly contributed to the prometastasis func-
tions of Jagged1. On the other hand, our coculture studies
revealed that Jagged1 induces the expression and secretion of
IL-6 from osteoblasts via activation of the Notch-signaling
cascade, in turn conferring an osteoblast-dependent prolifera-
tive advantage to tumor cells. IL-6 is associated with a poor
prognosis in breast cancer (Salgado et al., 2003) and is capable
of supporting tumor growth in the bone microenvironment
(Sasser et al., 2007). In neuroblastoma and multiple myeloma,
stromal-derived IL-6 has been shown to be an important medi-
ator between cancer cells and the bone microenvironment by
supporting tumor survival and affecting osteoclast differentia-
tion, respectively (Ara et al., 2009; Mitsiades et al., 2006). In
our present study the pathological role of IL-6 is further extended
to its involvement in Jagged1-mediated bone metastasis via an
osteoblast-dependent positive feedback mechanism.
The Notch pathway is also an important determinant of osteo-
clast maturation and function in the physiological setting
(Yamada et al., 2003). Transgenic mouse models have shown
that functional loss of particular Notch isoforms in pre-osteo-
clasts can increase osteoclastogenesis (Bai et al., 2008).
Conversely, Jagged1-mediated Notch signaling has also been
shown to promote osteoclast activation (Fukushima et al.,
2008). These controversial results suggest, once again, a poten-
tial context-dependent role for the Notch pathway in osteoclas-
togenesis. However, to our knowledge, the role of Notch
signaling in regulating osteoclast function in pathological condi-
tions such as bone metastasis has not been delineated. The
severe osteolytic pathology in mice inoculated with JAG1 OE
tumor cells pointed to an effect of tumor-derived Jagged1 on
osteoclastogenesis. We found that Jagged1 can enhance osteo-
clastogenesis in primary bone marrow cell cocultures. The func-
tional role of Jagged1 as a direct mediator of osteoclast differen-
tiation was further validated using tumor cell cocultures with two
different osteoclast cell lines and the application of pure re-
combinant Jagged1. Not only did we observe a greater number
of osteoclasts in JAG1 OE cocultures, we also noticed a more
differentiated population that was unequivocally confirmed by
transcriptional profiling of osteoclast differentiation markers.
Overall, our in vivo and in vitro studies demonstrated a direct
and strong impact of Jagged1 in promoting osteoclastogenesis
and bone destruction.
Jagged1 as a Central Mediator of Notch-TGFb Signaling
Crosstalk in Bone Metastasis
The important contribution of bone-derived TGFb during osteo-
lytic bone metastasis is well established. Bone is a rich reservoir
of TGFb, which is released into the bone microenvironment
during osteolytic bone metastasis. Genetic or pharmacological
disruption of TGFb signaling potently reduces the development
of bone metastasis, emphasizing the importance of the TGFb
pathway in supporting the bone metastatic ability of tumor cells
(Korpal et al., 2009; Yin et al., 1999). However, the functional
downstream targets of the TGFb-SMAD pathway in bonemetas-
tasis remain poorly defined. Here, we show that Jagged1 is
a SMAD-dependent target of TGFb in breast cancer bonemetas-
tasis and that reestablishing JAGGED1 expression in a SMAD4
KD background restores the potency of tumor cells to generate
osteolytic bone metastasis. Thus, Jagged1 may mediate
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the vicious cycle of osteolytic bone metastasis. Intriguingly, we
also observed an upregulation of the Tgfb1 transcript in osteo-
blasts and osteoclasts upon activation of the Notch pathway
(Figure 4B; FigureS5G). However, administration of a neutralizing
antibody preventing the feedback of TGFb on JAG1 OE tumor
cells in osteoblast cocultures did not significantly alter their
growth properties (data not shown). Collectively, these studies
suggest that the release of bone-derived TGFb in response to
osteolysis, as opposed to de novo expression of osteoblast-
derived TGFb in response to Notch activation, is likely to be
more critical in the pathogenesis of Jagged1-mediated bone
metastasis. The Notch and TGFb-signaling pathways have
been shown to converge in diverse contexts such as epithelial
to mesenchymal transition (Zavadil et al., 2004) and the patho-
genesis of glomerular disease (Niranjan et al., 2008). Our results
show that these two pathways once again link up to constitute
a potent positive feedback loop between tumor cells and the
bone microenvironment to promote osteolytic bone metastasis.
GSIs as Therapy against Breast Cancer BoneMetastasis
Disruption of the Notch pathway has been achieved through
pharmacological inhibition of g-secretase, the enzymatic
complex that mediates the final cleavage of the Notch receptor
leading to release of its transcription-activating intracellular
domain. These pharmacological agents, known as GSIs, are
gaining recognition as potential anticancer agents (Rizzo et al.,
2008). However, it has not been definitively determined whether
cancer progression is impeded by disrupting Notch signaling in
the tumor cells or the associated stromal microenvironment.
Moreover, a few studies have revealed a subset of cancer cell
lines that are resistant to GSI treatment. Consistently, our prolif-
eration assays and primary tumor xenografts of MDA231
sublines revealed no difference between control and MRK-
003-treated groups, particularly at relatively low concentrations
that were sufficient to inhibit the Notch pathway in bone-specific
cells. These findings were supported by another study in which
a panel of six breast cancer cell lines, including MDA231, were
treated with three distinct GSIs, and no effect on proliferation/
survival was observed for two of the compounds, whereas the
third elicited cytostasis at concentrations similar to that of a pro-
teosome inhibitor, suggesting nonspecific g-secretase-indepen-
dent effects (Han et al., 2009). We used an extensive series of
experiments to show that MRK-003 disrupts bone-specific
tumor functions by inhibiting the Jagged1-Notch mediated
crosstalk between tumor cells and supporting bone cells. These
findings support the application of GSIs as therapy against bone
metastasis, most probably at a dosage that would circumvent
drug-associated toxicities such as gastrointestinal irritation.
In conclusion we have revealed an important stroma-depen-
dent mechanism for the Notch ligand Jagged1 in promoting
breast cancer metastasis to the bone. Our study also revealed
the convergence of two developmentally conserved signaling
pathways—TGFb and Notch—in the pathological crosstalk
between tumor cells, bone-specific cells, and the bone matrix
during breast cancer bone metastasis. Importantly, we have
provided robust preclinical evidence for GSIs as therapeutic
agents against bone metastasis by targeting the tumor-associ-
ated stroma.CEXPERIMENTAL PROCEDURES
Tumor Xenografts and Bioluminescence Analysis
All procedures involving mice and experimental protocols were approved by
Institutional Animal Care and Use Committee (IACUC) of Princeton University.
For bone metastasis studies, 105 tumor cells were injected into the left cardiac
ventricle of anesthetized female athymic Ncr-nu/nu or BALB/c mice. Develop-
ment of metastases was monitored by BLI. Anesthetized mice were retro-
orbitally injected with 75 mg/kg D-Luciferin. Bioluminescence images were
acquired with a Xenogen IVIS 200 Imaging System. Analysis was performed
with Living Image software by measuring photon flux in the hindlimbs of
mice. Data were normalized to the signal on day 7. Bone metastasis-free
survival curves represent the time point at which each mouse developed
bone metastasis by threshold BLI signals in the hindlimbs. For the orthotopic
xenograft model, mammary fat pad injections and primary tumor size
measurements were performed following the procedure described previously
(Minn et al., 2005).
Osteoblast Coculture, Gene Expression, and Microarray Analysis
MC3T3-E1 cells were seeded at 2 3 105 cells/well in 12-well plates. After
confluence was achieved, luciferase/GFP-labeled (GFP+) control and JAG1
OE cells were added at 1 3 104 cells/well in triplicate and treated with
DMSO or 1 mM MRK-003. Media supplemented with appropriate drugs were
changed every 2 days. After 6 days the coculture was subjected to a luciferase
assay to selectively quantify the number of tumor cells. These values were
normalized against luciferase quantification of 12-well plates seeded with
tumor cells alone.
For gene expression analysis, MC3T3-E1 cells were grown to confluence in
10 cm culture dishes. The 23 105 GFP+ control or JAG1 OE cells were seeded
onto the plate in osteoblast media. Cell sorting was performed to purify the
GFP-negative MC3T3-E1 osteoblasts 5 days after initial coculture. RNA from
FACS-separated MC3T3-E1 cells was collected in RLT lysis buffer, extracted
with RNeasy Mini Kit (QIAGEN), and subjected to quantitative RT-PCR.
For microarray analysis the quality of the FACS-separated MC3T3-E1 RNA
samples was monitored using the 2100 bioanalyzer (Agilent) before gene
expression profiling with the Agilent mouse 4344k microarrays. To find genes
regulated by JAGGED1 and MRK-003 in osteoblasts, expression data of
MC3T3-E1 under the indicated coculture and treatment conditions were
generated and normalized by the array median, and probes were filtered by
the expression levels. Probes with >2-fold changes in MC3T3-E1 cells cocul-
tured with JAG1 OE tumor cells relative to vector-control tumor cells were
identified as the regulated genes.
Osteoclastogenesis Coculture Assay
After seeding 5 3 104 control or JAG1 OE tumor cells/well into 12-well plates,
murine pre-osteoclast Raw 264.7 (23 105 cells/well) or MOCP5 (53 105 cells/
well) cells in media containing 30 ng/ml RANKL and DMSO or 1 mMMRK-003
were added the next day. Media were changed every 2 days. TRAP staining
was performed on day 6 using a leukocyte acid phosphatase kit (Sigma).
TRAP+-multinucleated cells were scored as mature osteoclasts. The number
of nuclei per osteoclast was quantified using TRAP-stained images. Mouse-
specific qRT-PCR primers were used to selectively quantify Raw264.7 osteo-
clast gene expression levels after 6 days of coculture.
For primary osteoclast coculture assays, bone marrow cells were flushed
out from femora and tibiae of 4- to 6-week-old wild-type FVB mice and plated
in basal culture medium overnight. The next day, nonadherent cells were
added at 13 106/well to 12-well plates that were previously seeded with either
control or JAG1 OE tumor cells supplemented with 50 ng/ml RANKL and
50 ng/ml M-CSF. Medium was changed every 3 days. TRAP staining and
scoring were performed on days 10–12 as described above.
Statistical Analysis
Results are presented as average ± standard deviation (SD) or as average ±
standard error of the mean (SEM), as indicated in figure legends. Comparisons
between Kaplan-Meier curves were performed using the log rank test. BLI
signals were analyzed by unpaired, two-sided, independent Student’s t test
without equal variance assumption, nonparametric Mann-Whitney test, orancer Cell 19, 192–205, February 15, 2011 ª2011 Elsevier Inc. 203
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Jagged1 Promotes Breast Cancer Bone MetastasisANOVA. All other comparisons were analyzed by unpaired, two-sided, inde-
pendent Student’s t test without equal variance assumption.
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